Screening of new KL-6-associated mucins useful in clinical diagnosis of interstitial pneumonitis
筛选可用于间质性肺炎临床诊断的新型 KL-6 相关粘蛋白
基本信息
- 批准号:06670618
- 负责人:
- 金额:$ 1.41万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1994
- 资助国家:日本
- 起止时间:1994 至 1995
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Screening of murine monoclonal antibodies which react with novel antigenic deternlinants on KL-6 molecules was performed last year.EK-7 monoclonal antibody was finally selected for the purpose this year.EK-7 antibody was IgM and reacted with an antigenic determinant different from the determinant recognized with KL-6 antibody. The antigenic determinant was peptide portion of KL-6 molecules.The PEP-76 molecule in serum which was detected by a sandwich type of enzyme immunoasssay using EK-7 antibody as a catcher and KL-6 antibody as a tracer was designated as PEP-76. The method using 96-well EIA plates was similar to that for the measurement of KL-6.Study population was 51 healthy individuals, 13 patients with idiopathic interstitial pneumonia and 12 patients with sarcoidosis.PEP-76 level was 0.9 (0.9-3.9) U/ml [median (range)] in healthy individuals, 54 (0.9-580) U/ml in idiopathic interstitial pneumonia, and 1 (0.9-13) U/ml in sarcoidosis. Both the levels in idiopathic interstitial pneumonia and sarcoidosis were statistically higher than that in healthy individuals. when the cut-off level of PEP-76 was determined at 2.7 U/ml from the distribution of the levels of healthy individuals, the positive rate was 92% in idiopathic interstitial pneumonia and 33% in sarcoidosis. The sensitivity of PEP-76 was higher than that of KL-6 in same sera from patients with interstitial pneumonitis.These observations indicate that PEP-76 is a novel serum marker for the diagnosis of interstitial pneumonitis.
去年筛选了能与KL-6分子上的新抗原决定簇反应的鼠单克隆抗体,今年最终选择了EK-7单克隆抗体,EK-7抗体为IgM,与KL-6抗体识别的抗原决定簇不同。用EK-7抗体作捕捉剂,KL-6抗体作示踪剂,用夹心酶免疫法检测血清中PEP-76分子,命名为PEP-76。采用96孔酶免疫分析板测定PEP-76,方法与KL-6测定法相似,研究对象为51例健康人,13例特发性间质性肺炎和12例结节病患者,PEP-76水平为0.9(0.9-3.9)U/ml [中位数(范围)],特发性间质性肺炎为54(0.9-580)U/ml,结节病为1(0.9-13)U/ml。特发性间质性肺炎和结节病患者血清中的P-gp水平明显高于健康人。根据健康人PEP-76水平的分布确定PEP-76的临界水平为2.7U/ml时,特发性间质性肺炎的阳性率为92%,结节病为33%。PEP-76对间质性肺炎的敏感性高于KL-6,提示PEP-76是诊断间质性肺炎的一种新的血清标志物。
项目成果
期刊论文数量(38)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
横山 彰仁、他: "間質性肺炎における血清トロンボモジュリンの検討" 日本胸部疾患学会雑誌. 32. 951-955 (1994)
Akihito Yokoyama 等:“间质性肺炎中血清血栓调节蛋白的检查”日本胸科疾病学会杂志 32. 951-955 (1994)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yokoyama A,et al.: "Circulating interleukin-6 levels in patients with bronchial asthma" Am J Respir Crit Care Med. 151. 1354-1358 (1995)
Yokoyama A 等人:“支气管哮喘患者的循环白细胞介素 6 水平”Am J Respir Crit Care Med。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yokoyama A,Kohno N,Fujino S,Hamada H,Inoue Y,Fujioka S,Ishida S,Hiwada K.: "Circulating interleukin-6 levels in patients with bronchial asthma" Am J Respir Crit Care Med. 151. 1354-1358 (1995)
Yokoyama A、Kohno N、Fujino S、Hamada H、Inoue Y、Fujioka S、Ishida S、Hiwada K.:“支气管哮喘患者的循环白细胞介素 6 水平”Am J Respir Crit Care Med。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yokoyama A,et al.: "Evaluation of soluble interleukin-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases" Clin Exp Immunol. 100. 325-329 (1995)
Yokoyama A 等人:“间质性肺病患者血清和上皮内衬液中可溶性白细胞介素 6 受体浓度的评估”Clin Exp Immunol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Fujioka S,et al.: "Ubenimex activates the E-cadherin-mediated adhesion of a breast cancer cell line YMB-S" Jpn J Cancer Res. 86. 368-373 (1995)
Fujioka S 等人:“Ubenimex 激活乳腺癌细胞系 YMB-S 的 E-钙粘蛋白介导的粘附”Jpn J Cancer Res。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KOHNO Nobuoki其他文献
KOHNO Nobuoki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KOHNO Nobuoki', 18)}}的其他基金
Anti KL-6 antibody enhances the effects of molecular targeted drug
抗KL-6抗体增强分子靶向药物疗效
- 批准号:
23659433 - 财政年份:2011
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Comparative studies of a clinical features and genomic analysis in patients with interstitial lung disease and drug induced lung injury
间质性肺疾病和药物性肺损伤患者临床特征和基因组分析的比较研究
- 批准号:
19390224 - 财政年份:2007
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The Study on KL-6 as Morbidity Ornamentation Factor and Prognosis Factor of Idiopathic Interstitial Pneumonia.
KL-6作为特发性间质性肺炎发病影响因素和预后因素的研究。
- 批准号:
14370197 - 财政年份:2002
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The Establishment of KL-6 Associated New Serum Markers Using High Sensitive Electrochemiluminescence Immunoassay.
使用高灵敏电化学发光免疫分析法建立 KL-6 相关新血清标志物。
- 批准号:
13557051 - 财政年份:2001
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
DEVELOPMENT OF A LUNG CANCER TREATMENT USING ANTI-KL-6/MUC1 MULTI-MONOCLONAL ANTIBODIES
使用抗 KL-6/MUC1 多单克隆抗体开发肺癌治疗方法
- 批准号:
10670548 - 财政年份:1998
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical Significance of Anti-MUC1 Natural Autoantibody in Sera from Patients with Lung Cancer
肺癌患者血清中抗 MUC1 天然自身抗体的临床意义
- 批准号:
08670665 - 财政年份:1996
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Differentiation Induction of a Cell Line with a Monoclonal Antibody
用单克隆抗体诱导细胞系的分化
- 批准号:
03807040 - 财政年份:1991
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)